Nasdaq

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due ...

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has ...
Business Wire

Geron Announces Phase 1 Findings from Two-Part IMproveMF Study Presented at ASH Suggesting Tolerability of RYTELO™ (imetelstat) in Combination with Ruxolitinib as Frontline ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced ...
BioWorld

Acridine-thiadiazole hybrids as selective telomerase inhibitors for lung cancer

Researchers from Nirma University in India aimed to discover and develop novel small-molecule telomerase inhibitors derived from known scaffolds with improved efficacy and safety for lung cancer ...
Cure Today

Study Explores THIO Plus Immunotherapy in Advanced Lung Cancer

Dr. Thomas Jankowski explained that THIO, a telomerase inhibitor, is being studied with Libtayo to help overcome resistance in advanced lung cancer. The purpose of a recent study shared at the 2025 ...
Cure Today

EU Approves Rytelo for Transfusion-Dependent Anemia in Low-Risk MDS

Rytelo is approved for low-risk MDS patients with transfusion-dependent anemia, excluding those with isolated deletion 5q. Phase 3 IMerge trial data demonstrated significant reduction in red blood ...